Recent Company News

• 11:39 AM ET Apr 16, 2026
  

  FDA taking an initial step to advance testosterone therapy for men

• 01:13 AM ET Apr 16, 2026
  

  Bayer AG transferred hold at Deutsche Bank; prior rating was hold (€40.74, 0.00)

• 02:44 AM ET Apr 08, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:52 PM ET Apr 07, 2026
  

  Bayer AG executive says FY26 guidance unchanged following US announcement on patented pharmaceutical tariffs -- Reuters

• 12:03 PM ET Apr 02, 2026
  

  Regeneron announces EYLEA HD approved by FDA for dosing intervals up to 5 months for wAMD and DME ($754.93, -22.32)

• 08:12 AM ET Apr 02, 2026
  

  UK MHRA approves Hyrnuo to treat HER2+ non-small cell lung cancer (€38.99, -1.14)

• 04:52 PM ET Apr 01, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:48 AM ET Apr 01, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:17 AM ET Apr 01, 2026
  

  Bayer AG reportedly weighing US pharma expansion as turnaround picks up speed -- media report (€40.12, +0.73)

• 02:41 AM ET Apr 01, 2026
  

  Bayer's AskBio completes enrollment in Phase 2 Clinical Trial of AB-1002 investigational gene therapy for heart failure (€39.39, 0.00)